ONO Pharmaceutical Co. Ltd., in partnership with Bristol Myers Squibb, has received approval from the European Commission for a new perioperative regimen involving the use of Opdivo® (nivolumab) in combination with chemotherapy, followed by adjuvant Opdivo for the treatment of resectable, high-risk non-small cell lung cancer with PD-L1 expression levels of 1% or more. This approval marks a significant advancement in the treatment options available for patients with this type of lung cancer, supporting ONO Pharmaceutical and Bristol Myers Squibb's ongoing efforts to improve cancer care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.